Skip to main content

A biospecimen collection clinical trial for multiple cancers - PM2

A Canadian initiative to measure, predict and assess cancer treatment outcomes in patients treated with immunotherapy
Disease Site
Multi-Site Clinical Trials
Trial Code
PM2 CAN-IMPACT-IO ǀ NCT06630273
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to examine the DNA and RNA found in your blood cells and tumour. Researchers want to understand how the changes in the genome of your tumour before, during and post-treatment affect how your body responds to treatment.

Why is this study important?

This study is being done to enable collection and study of these blood and tissue samples. The results will also look at information on how other participants with your type of cancer who received immunotherapy responded to treatment.

Who can participate in this study?

This trial is for:

  • Individuals enrolled on specific CCTG immunotherapy trials
  • Individuals willing to provide blood and tissue samples (biopsy)
  • Individuals willing to allow the use of archived tissue samples if needed
What are the risks?
  • If you choose to take part in this study, there is a risk due to the blood collection or biopsy. Some of the most common risks include bruises due to blood collection and bruising, pain and bleeding due to the biopsy. You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will be asked for a blood sample, a tissue sample via a biopsy and permission to use an archived tissue sample if required.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The PM.2 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit https://clinicaltrials.gov/study/NCT06630273

Use this trial information for your conversation with your health care team

Participating centres

Information coming soon.